Cover Image
市場調查報告書

緩釋性眼內藥物遞輸系統

Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (Second Edition)

出版商 ROOTS ANALYSIS 商品編碼 299342
出版日期 內容資訊 英文 275 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
緩釋性眼內藥物遞輸系統 Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (Second Edition)
出版日期: 2015年05月25日 內容資訊: 英文 275 Pages
簡介

眼睛的構造和生理功能很複雜,將眼藥有效送到特定的地方極為困難。為了使眼藥遞送成功,必須克服幾個障礙。關於障礙,有眼淚稀釋藥物,結膜的淋巴節消除藥物,角膜、鞏膜及脈絡膜的藥物透過問題等。

本報告提供眼科疾病植入、微粒子藥物遞輸系統(DDS)的新興市場、已上市、正在開發移植的調查及其中長期性的發展可能性關注調查、產品簡介、銷售額預測,及主要企業的簡介等彙整。

第1章 序文

第2章 摘要整理

第3章 簡介

  • 概要
  • 眼結構
  • 眼內藥物遞輸系統
  • 對眼科疾病的藥物遞輸

第4章 市場概要

  • 調查範圍
  • 持續型藥物遞輸用的有限的上市眼科系統
  • pSivida主要的技術供應商
  • 開發平台分析
  • 生命週期經營管理工具
  • 遺傳基因療法

第5章 產品簡介、銷售額預測

  • 本章概要
  • 調查手法、前提條件
  • 整體市場規模、預測
  • Retisert (Bausch & Lomb, Inc. )
    • 產品概要
    • 開發、認證的歷史
    • 產品規格
    • 製造
    • 產品的優點
    • 相關風險
    • 銷售額實際成果
    • 銷售額預測 等
  • Vitrasert (Bausch & Lomb, Inc.)
  • Iluvien (Alimera Sciences)
  • Ozurdex (Allergan)
  • IBI-10090 (Icon Biosciences)
  • OTX-DP (Ocular Therapeutix)
  • Medidur (pSivida)
  • Bimatoprost Sustained Release Implant (Allergan)
  • NT-501 (Neurotech Pharmaceuticals)
  • Punctal Plug Delivery System (Mati Therapeutics)
  • OTX-TP (Ocular Therapeutix)
  • NT-503 (Neurotech Pharmaceuticals)
  • Unnamed, Novadur (Allergan)
  • ProDex (Taiwan Liposome Company)
  • 比較分析
    • 生物分解性系統
    • 非生物分解性系統

第6章 企業簡介

  • 本章概要
  • pSivida
    • 企業概要
    • 財務實際成果
    • 藥物遞輸技術
    • 藥物遞輸系統的組合
    • 聯盟
    • 最新趨勢 等
  • Allergan
  • Icon Biosciences
  • Ocular Therapeutix
  • Neurotech Pharmaceuticals
  • 參天製藥
  • Aciont Inc.
  • Envisia Therapeutics
  • GrayBug
  • Innocore Pharmaceuticals
  • OHR Pharmaceuticals
  • PolyActiva
  • TheraKine

第7章 創業投資的支援

  • 本章概要
  • 投資的實例/津貼、補助金的交付
  • 創業投資人的關注高漲
  • 資金籌措的分佈;各採購類型
  • 類別內的全投資額的分佈

第8章 最新聯盟趨勢

  • 本章概要

第9章 SWOT分析

  • 本章概要
  • 優勢
  • 弱點
  • 機會
  • 威脅

第10章 採訪記錄

第11章 結論

第12章 附錄1:表格形式資料

第13章 附錄2:企業、組織的清單

圖表清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: RA10039

Given the intricacy of the anatomy and physiology of the eye, it is quite challenging to deliver an ophthalmic drug effectively to a specific ocular site. Several barriers have to be overcome for a successful ocular drug delivery. These include dilution of a drug by tears, clearance of a drug by the lymphatic system of conjunctiva and drug permeation issues with respect to the cornea, sclera and choroid. Approximately 95% of the drug, in topical eye drops, is lost due to the aforementioned barriers.

The widening gap between the demand of novel treatments and supply of drugs/ systems is going to provide a major impetus to the sustained release ocular drug delivery market in the coming decade. Different ocular drug delivery systems have been devised for supplying drugs effectively to various parts of the eye. Contact lenses and punctal plugs are used to deliver drugs to the anterior segment of the eye while intravitreal implants and injectable particulate systems are used for drug delivery into the posterior segment of the eye. There are both advantages and disadvantages of the existing drug delivery systems; advancements are being made to enhance ocular bioavailability and retention time of the drug.

In the past few years, these implants and inserts have become one of the key focus areas of researchers and companies alike. Several venture capital firms have backed the smaller organizations working in this field. In addition, partnerships and collaborations have played a pivotal role in the advancement of the market.

Synopsis

The 'Sustained Release Ocular Drug Delivery Systems, 2015 - 2025 (2nd edition) ' report provides an extensive study of the emerging market of implants and particulate drug delivery systems (DDS) for ophthalmic diseases. The focus of this study is on commercial implants and those under development, their applications and the likely mid-term and long-term evolution. It is widely anticipated that such drug delivery systems have tremendous potential as they provide improved retention time compared to topical applications and offer convenience over regular intravitreal injections, mainly for posterior eye diseases.

The report covers various aspects such as technological progress, product pipeline, target indications, industry and academic research programs to assess new evolving opportunities. We have provided a competitive spider web analysis to compare different implants based on technical parameters (drug elution rate, amount of drug delivered, life of implant etc.) and their likely user friendliness. Our opinion and insights, presented in this study, were influenced by the discussions that we conducted with different ophthalmic implant developers in this industry.

The base year for the report is 2014. The report provides market forecasts for the following two time horizons: 2015 - 2020 and 2020 - 2025. In addition to the above, we have also provided our own independent perspective on the key drivers behind the growth of this market, likely challenges and potential threats. The research, analysis and insights presented in this report include the sales potential of various marketed and late stage pipeline ocular sustained drug delivery systemsbased on the current expected launch timelines, adoption rates and the estimated end-use price points.The figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • 1. More than 25 companies are currently working on developing sustained release drug delivery systems for the treatment of ocular indications. Examples of some key players include pSivida, Allergan, Ocular Therapeutix, Neurotech Pharmaceuticals, Icon BioScience and GrayBug.
  • 2. Vitrasert, launched in 1996, was the first ocular implant. It was, however, taken off the market in 2013. Only three more implants have received regulatory approval since 1996; these are Retisert, Ozurdex and Iluvien.
  • 3. Majority of the systems (52%) are in preclinical stage of development. Over 10 systems are currently undergoing late stage clinical trial studies. Once approved, these inserts are likely to provide a major impetus to the overall market.
  • 4. DME and Uveitis will provide the much needed boost to the sustained release ocular drug delivery systems market in the short-term. In the mid to long term, the growth will be fostered by launch of sustained release systems for glaucoma and AMD. In fact, more than 15 sustained release formulations are under development for the treatment of glaucoma.
  • 5. Interest of venture capital firms, licensing/ partnership opportunities will continue to act as key growth drivers of this market. During our research, we identified several instances where venture capitalists and other strategic investors have actively supported the research efforts.
  • 6. The overall market is likely to be more than USD 6.5 billion in the coming decade. The opportunity could be much higher in the outer years, especially driven by the regulatory approval of implants for delivery of biologics.

Research Methodology

Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Other analysts' opinion reports

While the focus has been on forecasting the market over the coming nine years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the ophthalmic drug delivery systemsmarket is headed in the short, mid and long term.

Chapter 3 provides a general introduction to the ophthalmic drug delivery market. We have discussed, in detail, the anatomy of the eye. The chapter also outlines details on different types of ocular drug delivery implants. In addition, several ocular indications, which are being targeted by sustained release implants, are also covered in this chapter.

Chapter 4 provides an overview of the ophthalmic drug delivery systems market with respect to the available marketed technologies and companies active in the field. We have provided a detailed pipeline of systems that are either marketed or are under clinical/ preclinical development. The chapter includes pipeline analysis by phase of development, system type, and indications targeted. It also covers the sustained release systems that are currently being evaluated by academic researchers and universities. In addition, we have also provided information on gene therapies that are being developed to provide a controlled treatment to several ocular indications.

Chapter 5 provides detailed profiles of 13 systems which are marketed and/ or arein late stages of clinical development (Phase II and Phase III). These profiles cover information on underlying technologies, development history, principal features (size of the implant, drug elution rate, life of the implant, related patents and intellectual property, nature of the insert) and current status of development. For each system, we have also estimated the future sales potential over the next ten years. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry's evolution.

Chapter 6 reviews the 13 leading companies which are active in the area of ophthalmology sustained release drug delivery technology. Each company profile includes information on the company overview, financial performance, marketed / pipeline systems, fundings, partnerships, and recent developments.

Chapter 7 provides information on several investment instances which have driven research in the area of sustained release ocular drug delivery systems. These investments are a testament to the growing interest of different stakeholders in this industry.

Chapter 8 covers details on the recent partnerships which have taken place in this industry. We have discussed the various partnerships models in existence and the most common forms of deals / agreements which have evolved over time.

Chapter 9 provides our analysis of the strengths, weaknesses, opportunities and threats in the ophthalmology drug delivery systems market, capturing the key elements likely to influence future growth.

Chapter 10 is a collection of transcripts based on our discussion with some of the leading players in the industry. Examples of companies interviewed include Neurotech Pharmaceuticals, Mati Therapeutics, On Demand Therapeutics and Euclid Systems.

Chapter 11 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 12 and 13 are appendices, which provide tabulated data and a list of companies mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Overview
    • 3.1. Introduction
  • 3.2. Structure of the Eye
  • 3.3. Ocular Drug Delivery Systems
    • 3.3.1. Implantable Ocular Drug Delivery Systems
    • 3.3.2. Particulate Drug Delivery Systems
  • 3.4. Ocular Drug Delivery: Commonly Targeted Ophthalmic Disorders
    • 3.4.1. Age-related Macular Degeneration
    • 3.4.2. Cytomegalovirus Retinitis
    • 3.4.3. Diabetic Retinopathy
    • 3.4.4. Diabetic Macular Edema
    • 3.4.5. Glaucoma
    • 3.4.6. Ocular Infection
    • 3.4.7. Uveitis
    • 3.4.8. Retinal Vein Occlusion

4. MARKET OVERVIEW

  • 4.1. Scope
  • 4.2. Limited Marketed Ocular Systems for Sustained Drug Delivery
  • 4.3. pSivida is the Key Technology Provider
  • 4.4. Sustained Release Ocular Drug Delivery Systems: Pipeline Analysis
    • 4.4.1. Distribution by Phase of Development
    • 4.4.2. Distribution by Nature of Drug Delivery Systems
    • 4.4.3. Distribution by Intraocular Placement of Drug Delivery Systems
    • 4.4.4. Distribution by Indication Targeted
    • 4.4.5. Novel Implants for Ocular Drug Delivery
    • 4.4.6. Initial Focus on Anti-Inflammatory Drugs
    • 4.4.7. Glaucoma: The Next Big Opportunity?
    • 4.4.8. Universities' Interest in Ocular Sustained Drug Delivery Systems Market
  • 4.5. Life Cycle Management Tool
  • 4.6. Gene Therapy

5. PRODUCT PROFILES AND SALES FORECAST

  • 5.1. Chapter Overview
  • 5.2. Methodology and Assumptions
  • 5.3. Overall Market Size and Forecast, 2015-2025
  • 5.4. Retisert (Bausch & Lomb, Inc)
    • 5.4.1. Product Overview
    • 5.4.2. Development and Approval History
    • 5.4.3. Product Specifications
    • 5.4.4. Manufacturing of Retisert
    • 5.4.5. Product Advantages
    • 5.4.6. Associated Risks
    • 5.4.7. Historical Sales
    • 5.4.8. Sales Forecast, 2015-2025
  • 5.5. Iluvien (Alimera Sciences)
    • 5.5.1. Product Overview
    • 5.5.2. Development and Approval History
    • 5.5.3. Product Specifications
    • 5.5.4. Manufacturing of Iluvien
    • 5.5.5. Product Advantages
    • 5.5.6. Associated Risks
    • 5.5.7. Iluvien Contraindications
    • 5.5.8. Historical Sales
    • 5.5.9. Competition
    • 5.5.10. Opportunity for Iluvien
    • 5.5.11. Sales Forecast, 2015-2025
  • 5.6. Ozurdex (Allergan)
    • 5.6.1. Product Overview
    • 5.6.2. Development and Approval History
    • 5.6.3. Product Specifications
    • 5.6.4. Product Advantages
    • 5.6.5. Associated Risks
    • 5.6.6. Historical Sales and Reimbursement
    • 5.6.7. Competition
    • 5.6.8. Sales Forecast, 2015-2025
  • 5.7. IBI-10090 (Icon Bioscience)
    • 5.7.1. Product Specifications
    • 5.7.2. Current Status of Development
    • 5.7.3. Clinical Trial Results
    • 5.7.4. Advantages
    • 5.7.5. Competition
    • 5.7.6. Sales Forecast, 2015-2025
  • 5.8. OTX-DP (Ocular Therapeutix)
    • 5.8.1. Product Specifications
    • 5.8.2. Current Status of Development
    • 5.8.3. Clinical Trial Results
    • 5.8.4. Product Advantages
    • 5.8.5. Competition
    • 5.8.6. Sales Forecast, 2015-2025
  • 5.9. Medidur (pSivida)
    • 5.9.1. Product Specifications
    • 5.9.2. Current Status of Development
    • 5.9.3. Clinical Trial Results
    • 5.9.4. Competition
    • 5.9.5. Sales Forecast, 2015-2025
  • 5.10. Bimatoprost Sustained Release Implant (Allergan)
    • 5.10.1. Product Specifications
    • 5.10.2. Current Status of Development
    • 5.10.3. Clinical Trial Results
    • 5.10.4. Product Advantages
    • 5.10.5. Competition
    • 5.10.6. Sales Forecast, 2015-2025
  • 5.11. NT-501 (Neurotech Pharmaceuticals)
    • 5.11.1. Product Specifications
    • 5.11.2. Current Status of Development
    • 5.11.3. Phase II Clinical Trial Results
    • 5.11.4. Product Advantages
    • 5.11.5. Sales Forecast, 2015-2025
  • 5.12. Punctal Plug Delivery System (Mati Therapeutics)
    • 5.12.1. Product Specifications
    • 5.12.2. Current Status of Development
    • 5.12.3. Clinical Trial Results
    • 5.12.4. Product Advantages
    • 5.12.5. Competition
    • 5.12.6. Sales Forecast, 2015-2025
  • 5.13. OTX-TP (Ocular Therapeutix)
    • 5.13.1. Product Specifications
    • 5.13.2. Current Status of Development
    • 5.13.3. Clinical Trial Results
    • 5.13.4. Product Advantages
    • 5.13.5. Competition
    • 5.13.6. Sales Forecast, 2015-2025
  • 5.14. NT-503 (Neurotech Pharmaceuticals)
    • 5.14.1. Product Specifications
    • 5.14.2. Current Status of Development
    • 5.14.3. Phase I Clinical Trial Results
    • 5.14.4. Product Advantages
    • 5.14.5. Sales Forecast, 2015-2025
  • 5.15. Unnamed, Novadur (Allergan)
    • 5.15.1. Product Specifications
    • 5.15.2. Current Status of Development
    • 5.15.3. Clinical Trial Results
    • 5.15.4. Sales Forecast, 2015-2025
  • 5.16. ProDex (Taiwan Liposome Company)
    • 5.16.1. Product Specifications
    • 5.16.2. Current Status of Development
    • 5.16.3. Product/ Technology Advantages
  • 5.17. Comparative Analysis of Sustained Release Ocular Drug Delivery Systems
    • 5.17.1. Biodegradable Systems
    • 5.17.2. Non-Biodegradable Systems

6. COMPANY PROFILES

  • 6.1. Chapter Overview
  • 6.2. pSivida
    • 6.2.1. Company Overview
    • 6.2.2. Financial Performance
    • 6.2.3. Durasert and Tethadur Technology
    • 6.2.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.2.5. Collaborations
    • 6.2.6. Recent Developments
  • 6.3. Allergan
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Novadur Technology
    • 6.3.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.3.5. Collaborations
    • 6.3.6. Recent Developments
  • 6.4. Icon Bioscience
    • 6.4.1. Company Overview
    • 6.4.2. Funding
    • 6.4.3. Verisome Technology
    • 6.4.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.4.5. Recent Developments
  • 6.5. Ocular Therapeutix
    • 6.5.1. Company Overview
    • 6.5.2. Financial Performance
    • 6.5.3. Funding
    • 6.5.4. Hydrogel Technology
    • 6.5.5. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.5.6. Recent Developments
  • 6.6. Neurotech Pharmaceuticals
    • 6.6.1. Company Overview
    • 6.6.2. Funding
    • 6.6.3. Encapsulated Cell Technology
    • 6.6.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.6.5. Collaborations
  • 6.7. Santen Pharmaceutical
    • 6.7.1. Company Overview
    • 6.7.2. Financial Performance
    • 6.7.3. Ophthalmology: Leading Marketed Drugs
    • 6.7.4. CHRONIJECT Microsphere Technology
    • 6.7.5. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.7.6. Collaborations
  • 6.8. Aciont Inc.
    • 6.8.1. Company Overview
    • 6.8.2. Funding
    • 6.8.3. Visulex Technology
    • 6.8.4. Sustained Release Ocular Drug Delivery Systems Portfolio
  • 6.9. Envisia Therapeutics
    • 6.9.1. Company Overview
    • 6.9.2. Funding
    • 6.9.3. Sustained Release Ocular Drug Delivery Technology
    • 6.9.4. Sustained Release Ocular Drug Delivery Systems Portfolio
  • 6.10. GrayBug
    • 6.10.1. Company Overview
    • 6.10.2. Funding
    • 6.10.3. Sustained Release Ocular Drug Delivery Technology
    • 6.10.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.10.5. GrayBug: In The News
  • 6.11. Innocore Pharmaceuticals
    • 6.11.1. Company Overview
    • 6.11.2. Sustained Release Ocular Drug Delivery Technology
    • 6.11.3. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.11.4. Collaborations
  • 6.12. OHR Pharmaceuticals
    • 6.12.1. Company Overview
    • 6.12.2. Financial Performance
    • 6.12.3. SKS Ocular Sustained Release Technology
    • 6.12.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.12.5. Collaborations
  • 6.13. PolyActiva
    • 6.13.1. Company Overview
    • 6.13.2. Funding
    • 6.13.3. Sustained Release Ocular Drug Delivery Technology
    • 6.13.4. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.13.5. Collaborations
  • 6.14. TheraKine
    • 6.14.1. Company Overview
    • 6.14.2. Sustained Release Ocular Drug Delivery Technology
    • 6.14.3. Sustained Release Ocular Drug Delivery Systems Portfolio
    • 6.14.4. Collaborations

7. VENTURE CAPITAL SUPPORT

  • 7.1. Chapter Overview
  • 7.2. Instances of Investments / Grants in Sustained Release Ocular Drug Delivery Market
  • 7.3. Growing Venture Capitalist Interest
  • 7.4. Distribution of Funding Instances by Type of Funding
  • 7.5. Distribution by Total Amount of Investment in a Category

8. RECENT PARTNERSHIPS

  • 8.1. Chapter Overview
    • 8.1.1. Partnership Models / Agreements
    • 8.1.2. Collaborations Amongst Stakeholders are on a Rise
    • 8.1.3. Product/ Technology Development, Acquisitions and Product/ Technology Licensing Are Preferred Modes of Collaboration
    • 8.1.4. Most Active Companies in Sustained Release Ocular Drug Delivery Systems

9. SWOT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Strengths
  • 9.3. Weaknesses
  • 9.4. Opportunities
  • 9.5. Threats

10. INTERVIEW TRANSCRIPTS

  • 10.1. Quinton Oswald, President and CEO, Neurotech Pharmaceuticals
  • 10.2. Bob Butchofsky, Founder and CEO, Mati Therapeutics
  • 10.3. John Santini, President and CEO, On Demand Therapeutics
  • 10.4. Michael A Ross, Chief Executive Officer and Allan Kaplan, Chief Financial Officer, Euclid Systems
  • 10.5. Other Anonymous Respondents

11. CONCLUSION

  • 11.1. With A Huge Potential, Market Likely to Evolve Rapidly in Mid-Long Term
  • 11.2. Ophthalmic Indications and Improved Patient Compliance Are Amongst the Several Growth Drivers
  • 11.3. Key Emerging Technologies: Novel Methods for Efficient Drug Delivery
  • 11.4. A Number of Opportunities Outweigh Existing Challenges
  • 11.5. Concluding Remarks

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES

List of Figures

  • Figure 4.1 Ocular Drug Delivery Implants: Approval Timeline
  • Figure 4.2 Sustained Release Ocular Drug Delivery Systems: Distribution by Phase of Development
  • Figure 4.3 Sustained Release Ocular Drug Delivery Systems: Distribution by Nature of System
  • Figure 4.4 Sustained Release Ocular Drug Delivery Systems: Distribution by Site of Intraocular Placement
  • Figure 4.5 Sustained Release Ocular Drug Delivery Systems: Distribution by Target Indication
  • Figure 4.6 Sustained Release Ocular Drug Delivery Systems, University Research: Distribution by Target Indication
  • Figure 4.7 Lucentis Sales, 2010-2014 (USD Million)
  • Figure 4.8 Lumigan Sales, 2010-2014 (USD Million)
  • Figure 5.1 Overall Sales Forecast, Short-Mid Term (2014 - 2020), USD Million (Base Scenario)
  • Figure 5.2 Overall Sales Forecast, Mid- Long term (2020 - 2025), USD Million (Base Scenario)
  • Figure 5.3 Retisert Sales, 2010 - 2014 (USD Million)
  • Figure 5.4 Retisert Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
  • Figure 5.5 Retisert Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.6 Iluvien Sales, 2013-2014 (USD Million)
  • Figure 5.7 IVT Treated DME: US Market Share by Leading Drugs (%)
  • Figure 5.8 Iluvien Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
  • Figure 5.9 Iluvien Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.10 Ozurdex Development Timeline
  • Figure 5.11 Ozurdex Sales, 2010 - 2014 (USD Million)
  • Figure 5.12 Ozurdex Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
  • Figure 5.13 Ozurdex Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.14 IBI-10090 Sales Forecast: Short-Mid Term, USD Million (Base Scenario)
  • Figure 5.15 IBI-10090 Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.16 OTX-DP Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
  • Figure 5.17 Retisert, Iluvien, Ozurdex and Medidur: Percentage Share of Patients Reported to Have Developed IOP
  • Figure 5.18 Medidur Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
  • Figure 5.19 Bimatoprost Sustained Release Implant Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
  • Figure 5.20 NT-501 Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.21 PPDS Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
  • Figure 5.22 OTX-TP Sales Forecast: Mid-Long Term, USD Million (Base Scenario)
  • Figure 5.23 NT-503 Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.24 Unnamed (Novadur) Sales Forecast: Long Term, USD Million (Base Scenario)
  • Figure 5.25 Biodegradable Sustained Release Ocular DDS: Comparative Analysis
  • Figure 5.26 Non-Biodegradable Sustained Release Ocular DDS: Comparative Analysis
  • Figure 6.1 pSivida Revenues, 2012-Q3 2015 (USD '000)
  • Figure 6.2 Allergan Revenues, 2010-2014 (USD Million)
  • Figure 6.3 Allergan Revenues: Distribution by Business Segment, 2012-2014 (USD Million)
  • Figure 6.4 Allergan Specialty Pharmaceuticals Revenues: Distribution by Therapeutic Areas, 2014 (USD Million)
  • Figure 6.5 Allergan Revenues: Distribution by Sub-Segments of Medical Devices, 2014 (USD Million)
  • Figure 6.6 Allergan: Sales of Leading Marketed Ophthalmic Drugs (USD Million), 2013-2014
  • Figure 6.7 Icon Bioscience: Milestone Chart
  • Figure 6.8 Ocular Therapeutix Revenues, 2014 (USD'000)
  • Figure 6.9 Neurotech Pharmaceuticals: Milestone Chart
  • Figure 6.10 Santen Revenues: 2009-Q3 2015 (JPY Million)
  • Figure 6.11 Santen Revenues: Distribution by Business Segments, 2012-2014 (JPY Million)
  • Figure 6.12 Santen Revenues: Distribution by Sub-Segments of Pharmaceutical Business, 2014 (JPY Million)
  • Figure 6.13 Santen Revenues: Distribution by Sub-Segments of Other Businesses, 2014 (JPY Million)
  • Figure 6.14 OHR Pharmaceuticals: Operating Expenses, 2010- Q1 2015 (USD '000)
  • Figure 7.1 Sustained Release Ocular DDS Funding Instances: Cumulative Investments by Year, 2003-2015
  • Figure 7.2 Sustained Release Ocular DDS Funding Instances: Distribution by Categories
  • Figure 7.3 Sustained Release Ocular DDS Funding Instances: Distribution by Amount Invested in a Category (USD Million)
  • Figure 8.1 Sustained Release Ocular DDS Partnerships: Cumulative Partnerships by Year, 2001-2014
  • Figure 8.2 Sustained Release Ocular DDS Partnerships: Distribution by Type of Partnership
  • Figure 8.3 Sustained Release Ocular DDS Partnerships: Major Stakeholders
  • Figure 11.1 Ocular Drug Delivery Implants: Market Landscape And Growth Drivers
  • Figure 11.2 Sustained Release Ocular DDS Market, 2015, 2020, 2025 (USD Million)

List of Tables

  • Table 3.1 Eye: Description of Tissue Layers
  • Table 4.1 Availability of Ocular Drug Delivery Implants in the US and Europe
  • Table 4.2 Sustained Release Ocular Drug Delivery Systems: Pipeline
  • Table 4.3 Sustained Release Ocular Drug Delivery Systems: Research Projects at Universities
  • Table 4.4 Gene Therapies under Development for Ocular Diseases
  • Table 5.1 Current Development Phase and Expected Launch Year of Drug Delivery Systems (Phase II and Higher)
  • Table 5.2 Comparison of Iluvien with Currently Available Drugs for DME
  • Table 5.3 Vision Loss Associated with DME, Number of Patients in the US and Major EU Countries, 2012
  • Table 5.4 Market Potential for Iluvien in the US
  • Table 5.5 Approval of Ozurdex in Different Geographies
  • Table 5.6 IBI-10090: Completed Clinical Trials
  • Table 5.7 IBI-10090: Clinical Trial Results
  • Table 5.8 IBI-10090 and Marketed Topicals: Comparison of Anterior Chamber Cell Count
  • Table 5.9 IBI10090: Competitive Landscape
  • Table 5.10 OTX-DP: Ongoing Clinical Trials
  • Table 5.11 OTX-DP: Clinical Trial Results
  • Table 5.12 Medidur: Status of Development
  • Table 5.13 Medidur: Competitive Landscape
  • Table 5.14 Medidur and Available Drugs for Posterior Uveitis: Comparative Analysis
  • Table 5.15 Bimatoprost Implant: Patents
  • Table 5.16 NT-501: Ongoing Clinical Trials
  • Table 5.17 PPDS: Patents
  • Table 5.18 OTX-TP: Clinical Trials
  • Table 5.19 OTX-TP: Efficacy Results
  • Table 5.20 NT-503: Key Features
  • Table 5.21 NT503: Clinical Trial Result
  • Table 5.22 Brimonidine Implant: Patents
  • Table 5.23 Unnamed (Novadur): Clinical Trials
  • Table 5.24 Biodegradable Sustained Release Ocular DDS: Comparative Analysis
  • Table 5.25 Non-Biodegradable Sustained Release Ocular DDS: Comparative Analysis
  • Table 6.1 pSivida: Sustained Release Ocular DDS Pipeline
  • Table 6.2 pSivida: Revenues Received from Alimera Sciences (2009-2013), USD Million
  • Table 6.3 pSivida: Revenues Received from Restated Pfizer Agreement (2009-2013), USD Million
  • Table 6.4 Marketing Authorization Approvals: Iluvien (2014-2015)
  • Table 6.5 Allergan: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.6 Icon Bioscience: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.7 Ocular Therapeutix: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.8 Neurotech Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.9 NT-501: Orphan Drug and Fast Track Designations
  • Table 6.10 Neurotech: Research Collaborations
  • Table 6.11 Santen: Pipeline of Ophthalmology Drugs/ Systems
  • Table 6.12 Aciont Inc: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.13 Envisia Therapeutics: Company Overview
  • Table 6.14 Envisia Therapeutics: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.15 GrayBug: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.16 GrayBug: In The News
  • Table 6.17 Innocore Pharmaceuticals: Company Overview
  • Table 6.18 Innocore Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.19 OHR Pharmaceuticals: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.20 PolyActiva: Company Overview
  • Table 6.21 PolyActiva: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 6.22 TheraKine: Company Overview
  • Table 6.23 TheraKine: Sustained Release Ocular Drug Delivery Systems Pipeline
  • Table 7.1 List of Funding Rounds / Grants and Investors Involved
  • Table 8.1 Sustained Release Ocular Drug Delivery Systems: List of Partnerships
  • Table 9.1 Sustained Release Ocular Drug Delivery Systems: SWOT Analysis
  • Table 9.2 Development of Sustained Release Ocular Systems: Example Venture Capital Funding Instances
  • Table 12.1 Sustained Release Ocular Drug Delivery Systems: Distribution by Phase of Development
  • Table 12.2 Sustained Release Ocular Drug Delivery Systems: Distribution by Nature of System
  • Table 12.3 Sustained Release Ocular Drug Delivery Systems: Distribution by Site of Intraocular Placement
  • Table 12.4 Sustained Release Ocular Drug Delivery Systems: Distribution by Target Indication
  • Table 12.5 Sustained Release Ocular Drug Delivery Systems, University Research: Distribution by Target Indication
  • Table 12.8 Overall Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
  • Table 12.9 Overall Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
  • Table 12.10 Overall Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
  • Table 12.11 Overall Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
  • Table 12.12 Overall Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
  • Table 12.13 Overall Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
  • Table 12.14 Retisert Sales, 2010-2014 (USD Million)
  • Table 12.15 Retisert Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
  • Table 12.16 Retisert Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
  • Table 12.17 Retisert Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
  • Table 12.18 Retisert Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
  • Table 12.19 Retisert Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
  • Table 12.20 Retisert Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
  • Table 12.21 Iluvien Sales, 2013-2014 (USD Million)
  • Table 12.22 IVT Treated DME: US Market Share by Leading Drugs (%)
  • Table 12.23 Iluvien Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
  • Table 12.24 Iluvien Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
  • Table 12.25 Iluvien Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
  • Table 12.26 Iluvien Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
  • Table 12.27 Iluvien Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
  • Table 12.28 Iluvien Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
  • Table 12.30 Ozurdex Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Base Scenario)
  • Table 12.31 Ozurdex Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
  • Table 12.32 Ozurdex Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Conservative Scenario)
  • Table 12.33 Ozurdex Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
  • Table 12.34 Ozurdex Sales Forecast, Short-Mid Term (2015 - 2020), USD Million (Optimistic Scenario)
  • Table 12.35 Ozurdex Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
  • Table 12.36 IBI-10090 Sales Forecast, Short-Mid Term (2016 - 2020), USD Million (Base Scenario)
  • Table 12.37 IBI-10090 Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
  • Table 12.38 IBI-10090 Sales Forecast, Short-Mid Term (2016 - 2020), USD Million (Conservative Scenario)
  • Table 12.39 IBI-10090 Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
  • Table 12.40 IBI-10090 Sales Forecast, Short-Mid Term (2016 - 2020), USD Million (Optimistic Scenario)
  • Table 12.41 IBI-10090 Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
  • Table 12.42 OTX-DP Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
  • Table 12.43 OTX-DP Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
  • Table 12.44 OTX-DP Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
  • Table 12.45 Retisert, Iluvien, Ozurdex and Medidur: % Share of Patients Reported to Have Developed IOP
  • Table 12.46 Medidur Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
  • Table 12.47 Medidur Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
  • Table 12.48 Medidur Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
  • Table 12.49 Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
  • Table 12.50 Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
  • Table 12.51 Bimatoprost Sustained Release Implant Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
  • Table 12.52 NT-501 Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
  • Table 12.53 NT-501 Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
  • Table 12.54 NT-501 Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
  • Table 12.55 PPDS Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Base Scenario)
  • Table 12.56 PPDS Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Conservative Scenario)
  • Table 12.57 PPDS Sales Forecast, Mid-Long Term (2019 - 2025), USD Million (Optimistic Scenario)
  • Table 12.58 OTX-TP Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Base Scenario)
  • Table 12.59 OTX-TP Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Conservative Scenario)
  • Table 12.60 OTX-TP Sales Forecast, Mid-Long Term (2020 - 2025), USD Million (Optimistic Scenario)
  • Table 12.61 NT-503 Sales Forecast, Mid-Long Term (2021 - 2025), USD Million (Base Scenario)
  • Table 12.62 NT-503 Sales Forecast, Mid-Long Term (2021 - 2025), USD Million (Conservative Scenario)
  • Table 12.63 NT-503 Sales Forecast, Mid-Long Term (2021 - 2025), USD Million (Optimistic Scenario)
  • Table 12.64 Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 - 2025), USD Million (Base Scenario)
  • Table 12.65 Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 - 2025), USD Million (Conservative Scenario)
  • Table 12.66 Unnamed (Novadur) Sales Forecast, Mid-Long Term (2022 - 2025), USD Million (Optimistic Scenario)
  • Table 12.67 pSivida Revenues, 2012- Q3 2015 (USD'000)
  • Table 12.68 Allergan Revenues, 2010- 2014 (USD Million)
  • Table 12.69 Allergan Revenues: Distribution by Business Segment, 2012-2014 (USD Million)
  • Table 12.70 Allergan Specialty Pharmaceuticals Revenues: Distribution by Therapeutic Areas, 2014 (USD Million)
  • Table 12.71 Allergan Revenues: Distribution by Sub Segments of Medical Devices, 2014 (USD Million)
  • Table 12.72 Allergan: Sales for Leading Marketed Ophthalmic Drugs, 2013-2014 (USD Million)
  • Table 12.73 Ocular Therapeutix Revenues, 2014 (USD' 000)
  • Table 12.74 Santen Revenues, 2009- Q3 2015 (JPY Million)
  • Table 12.75 Santen Revenues: Distribution by Business Segments, 2012-2014 (JPY Million)
  • Table 12.76 Santen Revenues: Distribution by Sub-Segments of Pharmaceutical Business, 2013-2014 (JPY Million)
  • Table 12.77 Santen Revenues: Distribution by Sub-Segments of Other Businesses, 2013-2014 (JPY Million)
  • Table 12.78 OHR Pharmaceuticals: Operating Expenses, 2010-Q1 2015 (USD'000)
  • Table 12.79 Sustained Release Ocular DDS Funding Instances: Cumulative Investments by Year, 2003-2015
  • Table 12.80 Sustained Release Ocular DDS Funding Instances: Distribution by Categories
  • Table 12.81 Sustained Release Ocular DDS Funding Instances: Distribution by Amount Invested In a Category (USD Million)
  • Table 12.82 Sustained Release Ocular DDS: Cumulative Partnerships by Year, 2001-2014
  • Table 12.83 Sustained Release Ocular DDS Partnerships: Distribution by Type of Partnership
  • Table 12.84 Sustained Release Ocular DDS Partnerships: Major Stakeholders

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3i Plc
  • 2. AbbVie
  • 3. Abell Foundation
  • 4. Aciont, Inc.
  • 5. Actavis Plc
  • 6. Aerie Pharmaceutical
  • 7. Ain Shams University, Cairo, Egypt
  • 8. Alcon
  • 9. Alimera Sciences
  • 10. Allergan
  • 11. Alliance Medical Products Inc
  • 12. Alpha Associates
  • 13. Amgen Inc.
  • 14. Amorphex Therapeutics
  • 15. Apax Partners
  • 16. Ascension Health Ventures
  • 17. Atlas Venture
  • 18. Auritec Pharmaceuticals
  • 19. Avida Group
  • 20. Bausch & Lomb
  • 21. Baxter Venture
  • 22. Bayer Healthcare
  • 23. BCN Peptides
  • 24. Ben Venue Laboratories
  • 25. BioLight Israeli Life Sciences Investments Ltd.
  • 26. Brandon Biosciences
  • 27. Brecon Pharmaceuticals Ltd
  • 28. Brown Advisory
  • 29. Burrill and Company
  • 30. Byron Chemical Company
  • 31. Caja Navarra
  • 32. Canaan Partners
  • 33. Can-Fite BioPharma
  • 34. Catania University, Catania, Italy
  • 35. Centre for Eye Research Australia (CERA)
  • 36. Chang Gung University
  • 37. Chiron Vision Corporation
  • 38. Chongqing Medical University
  • 39. Clave Mayor
  • 40. Control Delivery Systems Inc.
  • 41. Corporación CAN
  • 42. Cullen Eye Institute, Baylor College of Medicine
  • 43. Domain Associates
  • 44. Duke Reading Center
  • 45. Duke University Medical Center
  • 46. Economic Committee for Health Products
  • 47. Enigma Therapeutics
  • 48. Envisia Therapeutics
  • 49. Ergo Equity
  • 50. ESBATech (a Biomedical Research Unit of Alcon)
  • 51. Euclid Systems
  • 52. EVS Glaucoma Therapeutics
  • 53. FARMABIOS SpA
  • 54. Federal University of Minas Gerais
  • 55. Flextronics International Ltd
  • 56. ForSight Labs
  • 57. Genentech
  • 58. GIMV
  • 59. GP Pharm
  • 60. GrayBug
  • 61. Hatteras Venture Partners
  • 62. Health Ventures
  • 63. Hercules Technology Growth Capital
  • 64. Hospital Research Center, Linkoping University
  • 65. Icon Bioscience
  • 66. IIT Roorkee
  • 67. Innocore
  • 68. Institute for Advanced Chemistry of Catalonia
  • 69. Institute of Nanoscience and Nanotechnology, Barcelona
  • 70. Intersouth Partners
  • 71. InterWest Partners
  • 72. Intrinsiq
  • 73. Inveready
  • 74. Johns Hopkins University School of Medicine
  • 75. Kyoto University, Faculty of Medicine
  • 76. le Venture Partners
  • 77. Lowy Medical Research Institute (LMRI)
  • 78. Maryland Biotechnology Center
  • 79. Maryland Venture
  • 80. Mati Therapeutics
  • 81. Mayflower
  • 82. Medicines and Healthcare products Regulatory Agency
  • 83. Melbourne University
  • 84. Memorial Sloan Kettering Cancer Center
  • 85. Merlin Biosciences
  • 86. MIT, Boston
  • 87. Monash University
  • 88. Morningside Group
  • 89. Nanomi
  • 90. Nanyang Technological University, Singapore
  • 91. National Eye Institute
  • 92. National Institute for Health and Care Excellence (NICE)
  • 93. National Institutes of Health Clinical Center
  • 94. National Tsing Hua University
  • 95. Navarra Civic Banking
  • 96. Neurotech Pharma
  • 97. New Enterprise Associates
  • 98. Nexus Medical Partners
  • 99. Nishi Eye Hospital, Osaka, Japan
  • 100. Novagali Pharma
  • 101. Novartis
  • 102. Nuclear Magnetic Resonance Unit, Barcelona
  • 103. Oakwood Laboratories
  • 104. OctoPlus
  • 105. Ocular Therapeutix
  • 106. Oculex Pharmaceuticals
  • 107. OHR Pharmaceuticals
  • 108. On Demand Therapeutics
  • 109. OncoSil Medical
  • 110. Ora Inc.
  • 111. Pappas Ventures
  • 112. Pfizer
  • 113. Polaris Ventures
  • 114. Polyactiva
  • 115. Pound Capital
  • 116. ProRetina Therapeutics
  • 117. pSivida Corp
  • 118. QLT Inc.
  • 119. Rainbow Biosciences
  • 120. Real Fleece FCR
  • 121. Regeneron
  • 122. Replenish, Inc.
  • 123. Roche
  • 124. Sanofi
  • 125. Santen
  • 126. Sanwa Kagaku Kenkyusho
  • 127. Sao Paulo State University
  • 128. School of Pharmacy, West Virginia University
  • 129. Signet Healthcare Partners
  • 130. Singapore Eye Research Institute
  • 131. SKS Ocular LLC
  • 132. Sodena (Navarra Development Society )
  • 133. Sparta LLC
  • 134. Specialized Therapeutics
  • 135. SV Life Sciences
  • 136. Taiwan Liposome Company
  • 137. The EMMES Corporation
  • 138. TheraKine
  • 139. Tulane University Medical Center
  • 140. United Centers for Advanced Research and Translational Medicine (ART)
  • 141. University of Barcelona
  • 142. University of California
  • 143. University of Cincinnati
  • 144. University of Colorado
  • 145. University of Florida
  • 146. University of Miami
  • 147. University of Nebraska
  • 148. University of Ottawa, Ottawa
  • 149. University of Pittsburgh
  • 150. University of Porto
  • 151. University of Waterloo
  • 152. Valeant Pharmaceuticals
  • 153. Venrock
  • 154. Versant Ventures
  • 155. Wakefield Group
  • 156. Wayne State University
  • 157. West LB
  • 158. Wilmer Eye Institute at Johns Hopkins University
  • 159. World Health Organization
  • 160. XOMA
  • 161. Yuwa capital
Back to Top